Neon Therapeutics, Inc. announced the completion of enrollment in NT-002, its Phase 1b clinical trial evaluating NEO-PV-01 with KEYTRUDA® (pembrolizumab) and chemotherapy in patients with untreated advanced or metastatic non-small cell lung cancer (NSCLC). NEO-PV-01 is a personal neoantigen vaccine custom-designed and manufactured based on the neoantigens identified by Neon’s proprietary bioinformatics engine, RECON®, as being the most therapeutically relevant for an individual patient. The trial, conducted in collaboration with Merck, is evaluating the safety, tolerability and efficacy of NEO-PV-01 in the metastatic setting. Patients enrolled in the trial undergo an initial tumor biopsy and then begin 12 weeks of treatment with pembrolizumab and chemotherapy. They receive the NEO-PV-01 vaccination at week 12 and treatment with pembrolizumab continues throughout the trial. The primary endpoint of the trial is safety. In addition, Neon is evaluating immune responses and clinical outcomes. Neon expects to report immune and clinical outcome data from NT-002 over the course of 2020.